clinical
De-risk your ophthalmic clinical trial with darc
Stratify patient cohorts
An increased DARC count is indicative of more active disease, allowing you to readily identify cohorts that are likely to progress and respond to your drug
1
Earlier efficacy readout
As DARC is predictive of future progression, it can be used as a surrogate, giving your an early measure of trial success rather than relying on slow moving structural and functional endpoints
2
Saves time and money
By mitigating the risk of clinical failure and obtaining results within weeks, you can make go/no-go decisions with confidence and reduce R&D costs
3
DARC in Phase 1b trials
TESTIMONALS
expertise at every stage
interested?
Book a MEETING WITH OUR EXPERTS TODAY
Dr. Alex Wilson,
Director of Corporate
Development & Quality
our publications
See below a sample of our research papers, click to read
